2′‐chlorodeoxyadenosine (2‐CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH‐S‐98 protocol of the histiocyte society

A prospective phase II Histiocyte Society study, LCH‐S‐98, evaluated the efficacy of 2‐chlorodeoxyadenosine (2‐CdA) monotherapy as salvage therapy in Langerhans cell histiocytosis (LCH).

[1]  Y. Bertrand,et al.  Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. , 2005, European journal of cancer.

[2]  F. Bontemps,et al.  Old and new insights into the mechanisms of action of two nucleoside analogs active in lymphoid malignancies: fludarabine and cladribine (review). , 2005, International journal of oncology.

[3]  W. Abdullah.  Pediatr Blood Cancer , 2004 .

[4]  R. Egeler,et al.  Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society—Late Effects Study Group , 2004, Pediatric blood & cancer.

[5]  J. Pretto,et al.  Successful treatment of Langerhans cell histiocytosis with 2‐chlorodeoxyadenosine , 2003, Respirology.

[6]  J. Koziol,et al.  Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  U. Pötschger,et al.  Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. , 2002, Medical and pediatric oncology.

[8]  C. Rodríguez-Galindo,et al.  Treatment of children with Langerhans cell histiocytosis with 2‐chlorodeoxyadenosine , 2002, American journal of hematology.

[9]  J. Góra‐Tybor,et al.  Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. , 2002, The hematology journal : the official journal of the European Haematology Association.

[10]  S. Raimondi,et al.  Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Michaelis,et al.  A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. , 2001, The Journal of pediatrics.

[12]  M. Tormo,et al.  [Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis. Study of 9 patients]. , 2001, Medicina clinica.

[13]  A. Sastre,et al.  Resultados del tratamiento con 2-clorodesoxiadenosina en la histiocitosis de células de Langerhans resistente o en recaída. Estudio de 9 pacientes , 2001 .

[14]  U. Pötschger,et al.  Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. , 2000, Klinische Padiatrie.

[15]  N. Flanagan,et al.  Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution. , 2000, Clinical and laboratory haematology.

[16]  A. Saven,et al.  Delayed Onset of Autoimmune Hemolytic Anemia Complicating Cladribine Therapy for Waldenström Macroglobulinemia , 2000, Leukemia & lymphoma.

[17]  R. Arceci,et al.  Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. , 1999, Medical and pediatric oncology.

[18]  B. Freidlin,et al.  Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Michaeli,et al.  Epstein-Barr virus-associated lymphoma after treatment of macroglobulinemia with cladribine. , 1999, The New England journal of medicine.

[20]  A. Saven,et al.  Cladribine activity in adult langerhans-cell histiocytosis. , 1999, Blood.

[21]  R. Larson,et al.  High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Gascoyne,et al.  Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. , 1998, Blood.

[23]  K. Stine,et al.  2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. , 1997, Medical and pediatric oncology.

[24]  E. Estey,et al.  Second cancer risk in hairy cell leukemia: analysis of 350 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Dimopoulos,et al.  Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine. , 1997, Leukemia & lymphoma.

[26]  M. Ratain,et al.  Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Juliusson,et al.  Cellular pharmacokinetics of 2-chloro-2'-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  A. Saven,et al.  2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Saven,et al.  2-Chlorodeoxyadenosine-Induced Complete Remissions in Langerhans-Cell Histiocytosis , 1994, Annals of Internal Medicine.

[30]  H. Gadner,et al.  LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society. , 1994, Medical and pediatric oncology.

[31]  M. Schell,et al.  2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.